- Home
- UEIC vs XFOR Comparison
UEIC vs XFOR Comparison
Compare UEIC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEIC
- XFOR
- Stock Information
- Founded
- UEIC 1986
- XFOR 2014
- Country
- UEIC United States
- XFOR United States
- Employees
- UEIC N/A
- XFOR N/A
- Industry
- UEIC Consumer Electronics/Appliances
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UEIC Consumer Staples
- XFOR Health Care
- Exchange
- UEIC Nasdaq
- XFOR Nasdaq
- Market Cap
- UEIC 88.0M
- XFOR 84.3M
- IPO Year
- UEIC 1993
- XFOR N/A
- Fundamental
- Price
- UEIC $4.36
- XFOR $3.80
- Analyst Decision
- UEIC Buy
- XFOR Strong Buy
- Analyst Count
- UEIC 2
- XFOR 3
- Target Price
- UEIC $10.00
- XFOR $34.17
- AVG Volume (30 Days)
- UEIC 67.4K
- XFOR 1.4M
- Earning Date
- UEIC 11-06-2025
- XFOR 11-12-2025
- Dividend Yield
- UEIC N/A
- XFOR N/A
- EPS Growth
- UEIC N/A
- XFOR N/A
- EPS
- UEIC N/A
- XFOR N/A
- Revenue
- UEIC $402,518,000.00
- XFOR $32,774,000.00
- Revenue This Year
- UEIC $0.57
- XFOR $1,307.51
- Revenue Next Year
- UEIC N/A
- XFOR N/A
- P/E Ratio
- UEIC N/A
- XFOR N/A
- Revenue Growth
- UEIC 4.00
- XFOR 5721.31
- 52 Week Low
- UEIC $4.24
- XFOR $1.35
- 52 Week High
- UEIC $12.50
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- UEIC 41.70
- XFOR 63.34
- Support Level
- UEIC $4.34
- XFOR $2.96
- Resistance Level
- UEIC $4.55
- XFOR $3.21
- Average True Range (ATR)
- UEIC 0.19
- XFOR 0.28
- MACD
- UEIC -0.01
- XFOR 0.02
- Stochastic Oscillator
- UEIC 22.64
- XFOR 57.76
About UEIC Universal Electronics Inc.
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.